CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for HLB BioStep Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

HLB BioStep Co Ltd
38, Academy-ro 79beon-gil, Yeonsu-gu
Phone: +82 328338899p:+82 328338899 INCHEON, 22014  South Korea Ticker: 278650278650
Business Summary
HLB bioStep Co Ltd, formerly KNOTUS Co Ltd, is a Korea-based company mainly engaged in non-clinical trial business. The Company operates through three segments. The Non-clinical Test Consignment Agency Business segment conducts non-clinical is mainly engaged in the test on newly developed substances such as new drugs ,and tests the efficacy and pharmacodynamics of substances. In addition, this segment is engaged in the test of the safety of substances. The Bioinfra Business segment is engaged in animal laboratory design, construction, and maintenance. In addition, this segment provides equipment delivery. The Pet Medical Business segment is engaged in the development of veterinary medicine and the sale of companion animal products.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8071 Medical laboratories
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chief Executive Officer, Director Yin SeongJung
Co-Chief Executive Officer, Director Do HyeongKim 41
Co-Chief Executive Officer, Director Jeong HwanMoon 54 3/31/2022 3/31/2022

General Information
Outstanding Shares: 84,195,522 (As of 9/30/2024)
Shareholders: 49,473
Stock Exchange: KDQ
Fax Number: +82 315726699


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024